Two Sigma Investments’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

Two Sigma Investments’s Portfolio VINC Stock Details VINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-711	Closed	-$10.2K	–	3564
2024 Q3	$10.2K	Sell	711 -140	-16%	-$1.92K	﹤0.01%	3050
2024 Q2	$13.8K	Buy	+851	New	+$21.4K	﹤0.01%	2949
2023 Q3	–	Sell	-522	Closed	-$13.6K	–	3285
2023 Q2	$13.6K	Hold	522	–	–	﹤0.01%	2936
2023 Q1	$10.9K	Sell	522 -25	-5%	-$560	﹤0.01%	2887
2022 Q4	$11.2K	Sell	547 -2,187	-80%	-$41.2K	﹤0.01%	2724
2022 Q3	$75K	Sell	2,734 -270	-9%	-$7.77K	﹤0.01%	2268
2022 Q2	$79K	Sell	3,004 -1,257	-30%	-$55.9K	﹤0.01%	2296
2022 Q1	$341K	Buy	4,261 +3,092	+264%	+$382K	﹤0.01%	2171
2021 Q4	$238K	Buy	1,169 +531	+83%	+$133K	﹤0.01%	3807
2021 Q3	$206K	Sell	638 -553	-46%	-$161K	﹤0.01%	3954
2021 Q2	$309K	Buy	+1,191	New	+$363K	﹤0.01%	3490

Other funds holding VINC

SRC

Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments's VINC Position: Q4 2024 in Review

Two Sigma Investments sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q4 2024, closing a stake of 711 shares — an estimated $10.2K sold.

Two Sigma Investments first reported a position in VINC in Q2 2021 and held it in 11 quarters. The position peaked at $341K in Q1 2022. 22 funds tracked by Wall St. Rank hold VINC as of Q4 2024.

Two Sigma Investments reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Two Sigma Investments sold 711 Vincerx Pharma, Inc. Common Stock shares in Q4 2024, an estimated $10.2K.
Two Sigma Investments first reported a position in Vincerx Pharma, Inc. Common Stock in Q2 2021 and held it in 11 quarters.
Two Sigma Investments's Vincerx Pharma, Inc. Common Stock position peaked at $341K in Q1 2022.
22 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q4 2024.

Based on Two Sigma Investments's 13F filing for Q4 2024, filed 14 Feb 2025.